

[Generate Collection](#)[Print](#)*Prior Art Search***Search Results - Record(s) 61 through 80 of 80 returned.**

61. [7772247](#). 28 Jul 05; 10 Aug 10. Substituted thieno[3,2-d]pyridines as inhibitors of the VEGF receptor and HGF receptor. Vaisburg; Arkadii, et al. 514/301; 514/217.07 514/233.8 514/253.04 514/256 514/260.1 514/265.1 514/300 540/607 544/117 544/127 544/278 544/280 544/333 544/362 546/113 546/114 546/15 . C07D495/04 20060101 C07D413/06 20060101 C07D413/12 20060101 C07D413/10 20060101 C07D413/04 20060101 A61K31/4365 20060101 C07D223/04 20060101 C07D487/04 20060101 C07D401/04 20060101 C07D471/04 20060101 A61K31/519 20060101 A61P9/10 20060101 A61P35/04 20060101 .
62. [7601716](#). 30 Apr 07; 13 Oct 09. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors. Dorsey; Bruce D., et al. 514/249; 544/117 544/350 544/405 546/268.1 548/518 . A61K31/4985 20060101 .
63. [7598049](#). 19 Nov 04; 06 Oct 09. Methods for diagnosis of Alzheimer's Disease in blood samples. Ray; Sandip, et al. 435/7.21; 600/300 702/19 702/23 . G01N33/567 20060101 A61B5/00 20060101 G01N31/00 20060101 G01N33/48 20060101 .
64. [7217570](#). 22 Aug 02; 15 May 07. Organotypic intestinal culture and methods of use thereof. Herlyn; Meenhard, et al. 435/397; 435/371 435/373 435/384 435/395 . C12N5/00 20060101 C12N5/02 20060101 C12N5/08 20060101 .
65. [6290949](#). 28 May 96; 18 Sep 01. Adenoviral vector for inhibiting restenosis. French; Brent A., et al. 424/93.2; 424/93.6 435/320.1 435/456 514/44R . A61K048/00 A01N063/00 C12N015/00 .
66. [5916585](#). 30 May 97; 29 Jun 99. Materials and method for the immobilization of bioactive species onto biodegradable polymers. Cook; Alonzo D., et al. 424/426; 523/115 977/788 977/931 . A61F002/28 .
67. [5853746](#). 28 Jun 96; 29 Dec 98. Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier. Hunziker; Ernst B.. 424/426; 424/450 424/499 514/944 514/953 514/965 . A61F002/28 A61K009/127 A61K009/50 .
68. [JP 2009126826 A](#). Antistress agent for suppressing increase of cytokine and/or chemokine due to secretion of adrenocorticotrophin after stress, comprises (omega)-methyl sulfinyl 4-8C alkyl isothiocyanate as active ingredient. SEKIYAMA A.
69. [US 20090028919 A1](#). New system useful for promoting engraftment of a hybrid lower limb artery bypass vascular graft in a mammal comprises a controller having an input and an output and a pressure/flow loop subsystem coupled to the controller. DANCU M.
70. [US 20080249352 A1](#). System, useful e.g. for studying hemodynamics in normal and diseased states, comprises pressure/flow system, specimen having region arranged in flow loop, and controller for receiving information and output for outputting control signals. DANCU M.
71. [US 20080234805 A1](#). System, useful e.g. for studying hemodynamics in normal and diseased states, comprises controller having input for receiving information and feedback information, and output for outputting control signals; and pressure/flow loop subsystem. DANCU M.
72. [US 20080234801 A1](#). System, useful e.g. for studying hemodynamics in normal and diseased states, comprises controller having input for receiving information and feedback information, and output for outputting control signals; and pressure/flow loop subsystem. DANCU M.
73. [WO 2008036374 A2](#). Method of allogeneic stem cell therapy without preconditioning of recipient for treating diseases e.g. inflammatory and neurological disorder, involves matching patient with stem cell source, manipulating and

administering source. ICHIM T E, et al.

☐ 74. [WO 2007149548 A2](#). Treating or preventing the onset of erectile dysfunction in a mammal comprises administering cells admixed with a factor and capable of inducing one or more biological activities, e.g., inhibiting neuronal cell dysfunction. ICHIM T E.

☐ 75. [WO 2007136673 A2](#). Treating disc degenerative disease comprises administering cells capable of increasing angiogenesis. ICHIM T E.

☐ 76. [WO 2007037561 A1](#). New activating agent of stem cells and/or progenitor cells comprising a thrombin like enzyme, used in regenerative medicine utilizing self-regeneration. CAI D, et al.

☐ 77. [WO 2005094888 A1](#). Therapeutic agent or transplant material used for regenerating damaged tissues, contains factor suppressing diffusion of mesenchymal stem-cell from damaged tissue and promoting migration of mesenchymal stem-cell to damaged tissue. KATO Y, et al.

☐ 78. [US 20050123526 A1](#). New therapeutic delivery system, useful for treating diseases associated with loss of neuronal function, such as Parkinson's disease and Alzheimer's disease, comprises electrical signal generator and genetically engineered stem cells. SHAFER L L.

☐ 79. [WO 2005026318 A2](#). Producing antigenic response, involves contacting antigen-presenting cell with A1 adenosine receptor activating agent to increase antigenic response of antigen-presenting cell to antigen. BORRON P, et al.

☐ 80. [US 6013853 A](#). A porous, polymeric implant which provides continuous release of a bioactive agent. ATHANASIOU K A, et al.

[Generate Collection](#)

[Print](#)

Terms	Documents
L1 same L4	80

[Prev Page](#)

[Next Page](#)

[Go to Doc#](#)